2018 Global Multiple Sclerosis Market Insights, Epidemiology and Forecasts to 2027 - Trends and Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "Multiple Sclerosis - Market Insights, Epidemiology and Market Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

According to research, the global market of Multiple Sclerosis was estimated to be USD 21.25 billion in 2016.

The prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45-49 years in both female and male participants.

The drugs marketed for the treatment of mainly include disease-modifying therapies (DMT) - Copaxone, Tecfidera, Gilenya, Tysabri, Avonex, Aubagio, Lemtrada, Ocrevus, Rebif , Betaseron, Extavia, Plegridy, Fampyra, and Zinbryta . Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Siponimod (Novartis), Ponesimod (Johnson and Johnson), Ozanimod (Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), and Mavenclad (Merck KgaA)] have been covered in the report.

Companies Mentioned:

  • AB Science
  • Acorda Therapeutics
  • Bayer Healthcare
  • Biogen
  • Celgene Corporation
  • Genentech
  • Genzyme
  • Johnson & Johnson
  • MedDay Pharma
  • Merck KGA
  • Novartis
  • Teva Pharmaceutical
  • TG Therapeutics

Key Topics Covered:

1. Report Introduction

2. Multiple Sclerosis Market Overview at a Glance

3. Disease Background and Overview: Multiple Sclerosis (MS)

4. Epidemiology and Patient Population

5. Epidemiology of Multiple Sclerosis

6. United States

7. Germany

8. France

9. Italy

10. Spain

11. United Kingdom

12. Japan

13. Treatment Algorithm

14. Unmet Needs

15. Marketed Drugs

16. Betaferon: Bayer Healthcare

17. Rebif: Merck KGA

18. Copaxone: Teva Pharmaceutical

19. Avonex: Biogen Idec. Limited

20. Tysabri: Biogen Idec. Limited

21. Fampyra/Ampyra: Acorda Therapeutics/Biogen Idec Ltd.

22. Gilenya: Novartis

23. Aubagio: Genzyme

24. Tecfidera: Biogen Idec Ltd.

25. Plegridy: Biogen Idec Ltd.

26. Lemtrada: Genzyme

27. Zinbryta: Biogen Idec

28. Ocrevus: Genentech

29. Mavenclad: Merck

30. Emerging Therapies

31. Global Market Size of Multiple Sclerosis (MS)

32. United States

33. EU5

34. EU-5 Broken Down by Countries

35. Japan

36. Trends observed in MS therapies Cost in United States

37. Generic Competition in MS Market

38. Market Drivers

39. Market Barriers

40. Appendix

41. Report Methodology

For more information about this report visit https://www.researchandmarkets.com/research/c38d2q/2018_global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs